Mibavademab
Based on 1 Customer Validation
Mibavademab (REGN4461) is a LEPR agonist monoclonal antibody. Mibavademab activates leptin receptor (leptin receptor) and LEPR signaling, enhances leptin (leptin)-induced STAT3 activity without competing with leptin binding, and binds with high affinity to the human LEPR extracellular domain. Mibavademab can be used for research on leptin deficiency.
For research use only. We do not sell to patients.
- Purity : ≥99.0%
- CAS No.: 2305770-44-7
- Molecular Weight:145.58 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
|
LEPR |
leptin receptor |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:aP2-nSrebp1cTg/+;Leprhu/hu (Tg) and nontransgenic Leprhu/hu (nonTg) (male; 27-30 weeks old)[2]
-
Dosage:10 mg/kg
-
Administration:s.c.; once weekly; 4 weeks
-
Result:Three days after dosing initiation, Tg mice had significantly lower body weights than control mAb-dosed Tg mice and consumed less food.
After 4 weeks of dosing, lowered lean mass in Tg mice compared with control mAb-dosed Tg mice and significantly reduced fat mass in Tg mice compared with control mAb-dosed Tg mice (Fig. 2B).
Ad libitum-fed blood glucose was normalized within 3 days and remained comparable to nonTg levels.
HbA1c was reduced on day 28 after dosing compared with baseline or control mAb.
On day 23, Tg mice were as insulin sensitive as control mAb-administered nonTg mice.
Plasma triglycerides were significantly lower in Tg mice.
Circulating ALT and AST were lower in Tg mice than in control mAb-dosed Tg mice.
Livers from Tg mice were 0.6 g heavier than livers from nonTg control mice and showed no increase in liver triglyceride content.
H&E-stained liver sections showed reduced hepatocyte vacuolation.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Leptin R/LEPR Protein, Human (HEK293, His, HY-P72524) can bind Mibavademab. The EC50 for this effect is 12.50 ng/mL. -
Flow cytometric analysis of 1X106 K562 cells with Mibavademab (HY-P990631, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2305770-44-7
-
Appearance Liquid
-
Molecular Weight 145.58 kDa
-
Color Colorless to light yellow
-
Synonyms
REGN4461
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)